AbbVie (ABBV) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.71, $0.06 better than the analyst estimate of $2.65. Revenue for the quarter came in at $16.62 billion versus the consensus estimate of $16.39 billion.

GUIDANCE:

AbbVie sees FY2026 EPS of $14.37-$14.57, versus the consensus of $14.22.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• AbbVie presents real-world Vraylar data at Psych Congress 2026
• Teva shares Phase 3 data on once-monthly schizophrenia injection